search
Back to results

AF Septal Pacing (Clinical Investigation Plan)

Primary Purpose

Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Pulmonary vein ablation
Sponsored by
Medtronic BRC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Paroxysmal Atrial Fibrillation

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patient referred to the center to undergo ablation of the pulmonary vein using radiofrequency (initial AF ablation, or redo procedure).
  • In case of paroxysmal AF the right atrium should be dilated as indicated by > 29 ml mm2 or the left atrium should be dilated as indicated by > 34 ml mm2.
  • Patient is willing and able to cooperate with the study procedure.
  • Patient is willing to provide the Informed Consent for their participation in the study.

Exclusion Criteria:

  • Patients under 18 years or over 80 years old.
  • Women who are currently pregnant or have a positive pregnancy test.
  • Patients with an implantable cardiac device.
  • Patients who already underwent an AF septal ablation procedure.

Sites / Locations

  • Gottsegen György Országos Kardiológiai Intézet
  • Maastricht Universitair Medisch Centrum (MUMC)
  • St. Antonius Ziekenhuis

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Persistent and Paroxtmal AF Patients

Arm Description

Patients with either paroxymal or persistent AF already referred to the center for Pulmonary Vein Ablation will be stimulated delivering a novel dual-stage pacing protocol to terminate atrial fibrillation usinf a ring of electrodes positioned on the septum.

Outcomes

Primary Outcome Measures

Number of Electrodes in a Stable Position
To assess Pacing Site Stability, the number of interatrial septal pacing electrodes which are successfully placed in a stable position, will be counted. A stable position in this study is defined as a location where the pacing threshold will be < 10 mA at a pacing pulse width of 1 msec. Stable pacing further requires that no ventricular capture will be induced during atrial stimulation at twice the atrial capture threshold.

Secondary Outcome Measures

Localized Atrial Capture
To assess Localized Atrial Capture the following endpoints will be considered: - the number of AF episodes in which local capture is recorded during atrial septal stimulation in at least one of the electrode positions
Termination of Atrial Tachyarrhythmia.
Termination of atrial tachyarrhythmia.

Full Information

First Posted
August 4, 2017
Last Updated
October 21, 2019
Sponsor
Medtronic BRC
search

1. Study Identification

Unique Protocol Identification Number
NCT03242941
Brief Title
AF Septal Pacing (Clinical Investigation Plan)
Official Title
AF Septal Pacing (Clinical Investigation Plan)
Study Type
Interventional

2. Study Status

Record Verification Date
October 2019
Overall Recruitment Status
Completed
Study Start Date
April 26, 2018 (Actual)
Primary Completion Date
July 20, 2018 (Actual)
Study Completion Date
December 21, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Medtronic BRC

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this non-randomized, non-controlled, acute, single-arm research study is to evaluate the feasibility to obtain a stable position of a ring of stimulation electrodes on the interatrial septum. The possibility to terminate atrial arrythmias will also be evaluated.
Detailed Description
The evidence of treating AF by pacing is limited, although these algorithms are of interest, since they appear to be safe and usually add little additional cost. Using a computer model, a new dual-stage septal pacing has been developed.The proposed septal pacing algorithm could suppress AF reentries in a more robust way than classical single site rapid pacing. The feasibility of pacing both atria simultaneously from a single lead placed in the interatrial septum has been previously demonstrated clinically. The septal pacing concept has also been successfully tested in a computer model of AF and in a pig model . Experimental studies are now needed to determine whether similar termination mechanisms and efficacies can be observed in humans. The purpose of this non-randomized, non-controlled, acute, single-arm research study is to evaluate the feasibility to obtain a stable position of a ring of stimulation electrodes on the interatrial septum

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Approximately 15 subjects with AF indicated for ablation of the pulmonary vein will be enrolled in the study. Participants will attend the Baseline visit and the Procedure visit. The baseline visit can be on the same day as the ablation procedure. Since it is an acute study, no follow-up visit will occur. The research procedure will be performed during an already scheduled ablation procedure. Subjects will be enrolled over a period of approximately 18 months
Masking
None (Open Label)
Allocation
N/A
Enrollment
16 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Persistent and Paroxtmal AF Patients
Arm Type
Experimental
Arm Description
Patients with either paroxymal or persistent AF already referred to the center for Pulmonary Vein Ablation will be stimulated delivering a novel dual-stage pacing protocol to terminate atrial fibrillation usinf a ring of electrodes positioned on the septum.
Intervention Type
Procedure
Intervention Name(s)
Pulmonary vein ablation
Intervention Description
After pulmonary vein isolation, during the routine waiting time of half an hour to confirm efficacy of the ablation, the septal catheter, already in place in right atrium, will be positioned on the interatrial septum. If the patient will not be in sinus rhythm, he/she will be externally cardioverted in order to determine pacing thresholds and impedances on all septal catheter electrodes. Next, atrial fibrillation will be induced by rapid atrial pacing.AF cycle length will be determined in the left atrial appendage, during 1 minute of atrial fibrillation using ablation catheter electrodes. Subsequently, a pacing scheme will be applied and capture on decapolar recording catheters, already in place for the standard ablation procedure will be assessed as well as AF termination.
Primary Outcome Measure Information:
Title
Number of Electrodes in a Stable Position
Description
To assess Pacing Site Stability, the number of interatrial septal pacing electrodes which are successfully placed in a stable position, will be counted. A stable position in this study is defined as a location where the pacing threshold will be < 10 mA at a pacing pulse width of 1 msec. Stable pacing further requires that no ventricular capture will be induced during atrial stimulation at twice the atrial capture threshold.
Time Frame
30 minutes
Secondary Outcome Measure Information:
Title
Localized Atrial Capture
Description
To assess Localized Atrial Capture the following endpoints will be considered: - the number of AF episodes in which local capture is recorded during atrial septal stimulation in at least one of the electrode positions
Time Frame
30 minutes
Title
Termination of Atrial Tachyarrhythmia.
Description
Termination of atrial tachyarrhythmia.
Time Frame
30 minutes

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient referred to the center to undergo ablation of the pulmonary vein using radiofrequency (initial AF ablation, or redo procedure). In case of paroxysmal AF the right atrium should be dilated as indicated by > 29 ml mm2 or the left atrium should be dilated as indicated by > 34 ml mm2. Patient is willing and able to cooperate with the study procedure. Patient is willing to provide the Informed Consent for their participation in the study. Exclusion Criteria: Patients under 18 years or over 80 years old. Women who are currently pregnant or have a positive pregnancy test. Patients with an implantable cardiac device. Patients who already underwent an AF septal ablation procedure.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lucas V.A. Boersma
Organizational Affiliation
St. Antonius Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Gottsegen György Országos Kardiológiai Intézet
City
Budapest
ZIP/Postal Code
1096
Country
Hungary
Facility Name
Maastricht Universitair Medisch Centrum (MUMC)
City
Maastricht
ZIP/Postal Code
6229 HX
Country
Netherlands
Facility Name
St. Antonius Ziekenhuis
City
Nieuwegein
ZIP/Postal Code
3435 CM
Country
Netherlands

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

AF Septal Pacing (Clinical Investigation Plan)

We'll reach out to this number within 24 hrs